DMT and the 5-HT2A receptor: how strong is the evidence that it is the main switch?

THE SHORT VERSION · SWIPE

▶ Watch it as a 20-second video

‹›

Almost every explainer says DMT “works on the 5-HT2A receptor”. That is the mainstream view, and it is probably right as far as it goes. This article sets out exactly what evidence supports it, where that evidence comes from (mice, cells, ayahuasca or pure DMT), and which experiment is still missing. For the molecule itself, see what is DMT; for other receptors, see DMT and the sigma-1 receptor.

What is the 5-HT2A receptor?

5-HT is the chemical shorthand for serotonin, and 5-HT2A is one of its many receptors: proteins that sit in cell membranes and change the cell’s behaviour when serotonin, or a molecule shaped like it, binds. A major review of psychedelic pharmacology states there is now a consensus that psychedelics are agonists or partial agonists at brain 5-HT2A receptors, with particular importance on those expressed on the apical dendrites of layer V pyramidal neurons in the neocortex (Nichols, 2016). In plain terms: psychedelics switch the receptor on, fully or partly, and the cells that matter most are large neurons in the outer layers of the cortex. Evidence: established for psychedelics as a class.

Two terms recur below. A “partial agonist” switches a receptor on, but less fully than the strongest possible activator would. An “antagonist” or blocker, such as ketanserin, occupies the receptor without switching it on, so it can be used to test whether an effect needs that receptor: if the blocker prevents the effect, the receptor is probably required. That logic is why blocking studies sit at the centre of this article. Evidence: established.

DMT is a close chemical cousin of serotonin, so it is no surprise that it binds serotonin receptors. It binds many of them, not just one: a review quotes a screen in which DMT bound nine serotonin receptor subtypes, including 5-HT1A, 5-HT2A, 5-HT2C and 5-HT7, across a wide range of strengths (Barker, 2018). The question is which of those contacts produces the effects people report. Evidence: established for binding; what each contributes is unresolved.

What do animal studies show about DMT and 5-HT2A?

The strongest single piece of evidence comes from mice. In a 2009 study that used computer predictions to find new drug targets, DMT was confirmed as a potent partial agonist at 5-HT2A, and it induced the head-twitch response, a rodent behaviour used as a predictor of hallucinogenic action, in normal mice but not in mice bred without the 5-HT2A gene. The authors also found DMT’s potency at 5-HT2A was about 100-fold better than at the sigma-1 receptor, and concluded that their observations support 5-HT2A as the primary target for DMT’s hallucinogenic effects (Keiser et al., 2009). Evidence: preliminary, from mice.

Drug-blocking studies in rodents point the same way. A review describes work in which a selective 5-HT2A blocker fully blocked both the head twitch and the discriminative-stimulus effects of DMT (a test of whether animals can tell a drug apart from a control), while a 5-HT2C blocker had little or no effect. The same review notes that DMT produces fewer head twitches than most other psychedelics, and none in one mouse strain (Carbonaro and Gatch, 2016). Evidence: preliminary, from rodents.

5-HT2A also shows up in rat-cell studies of neuron growth. In cultured rat cortical neurons, the 5-HT2A blocker ketanserin completely abolished the ability of DMT, LSD and another psychedelic to promote the growth of neuron branches and spines; separately, DMT increased dendritic spine density in rat prefrontal cortex 24 hours after one dose (Ly et al., 2018). This is a cell and rat finding, not evidence of anything in the human brain; see is DMT neuroprotective?. Evidence: preliminary.

What is the human evidence?

The best human evidence comes from ayahuasca. In a double-blind, randomized, placebo-controlled study, 12 healthy, experienced volunteers each had four sessions combining ayahuasca or placebo with ketanserin or placebo (amounts not reproduced here). Ayahuasca reduced EEG power in the delta, theta and alpha bands, and lower alpha activity in the back of the brain went with more intense visual imagery. Pretreatment with ketanserin inhibited the brain-wave changes and attenuated the intensity of the subjective experience (Valle et al., 2016). Evidence: preliminary, from one small study.

The authors themselves point out that, before their study, the role of 5-HT2A in ayahuasca’s effects “has not been tested experimentally”, and they describe ayahuasca as containing DMT plus β-carboline alkaloids that inhibit the enzyme MAO (Valle et al., 2016). So the result shows that 5-HT2A matters for ayahuasca; it does not isolate DMT. The blockade attenuated the experience rather than abolishing it. For how the two differ, see ayahuasca vs DMT. Evidence: established for that limit.

Has anyone blocked 5-HT2A before giving people pure DMT?

For two other psychedelics, the decisive human test has been done. Ketanserin fully blocked the general subjective effects of LSD in healthy volunteers (Preller et al., 2017), and blocked psilocybin’s effects in a dose-dependent way (Vollenweider et al., 1998). For pure DMT, given by injection or inhalation, we found no such study. A Europe PMC search on 20 October 2026 for titles pairing ketanserin or 5-HT2A blockade with DMT or ayahuasca returned no results, and broader searches surfaced only reviews, animal work and the ayahuasca study above. Evidence: established that the experiment is not in the indexed literature.

One registered trial in Basel uses ketanserin with DMT, but not as a pretreatment. The LPD study, listed as recruiting, compares LSD, psilocybin and a DMT infusion in healthy participants, and gives ketanserin three hours in, so that effect duration is standardized across the three drugs (ClinicalTrials.gov, NCT06899334). Blocking an effect that is already under way is a different question from whether the effect needs 5-HT2A in the first place. Evidence: established for the registry design.

Does DMT act on other receptors too?

Some findings do not fit a one-receptor story. In a double-blind, randomized, placebo-controlled study of 12 experienced volunteers given intravenous DMT at a sub-hallucinogenic level, pretreatment with pindolol, which blocks the 5-HT1A receptor, intensified DMT’s subjective effects with a moderate effect size. The authors suggest 5-HT1A has a functional role in psychedelic effects. Blood pressure also rose with the combination (Zahid et al., 2026). It is one small study, so the result needs repeating. Evidence: preliminary.

In cell studies, one signalling response to DMT persisted even in the presence of ketanserin, and DMT also binds trace amine-associated receptors and the sigma-1 receptor (Barker, 2018). None of these has been shown to drive the experience in people. The sigma-1 story, including why it needs much higher concentrations, is covered in DMT and the sigma-1 receptor. Evidence: unresolved.

Do brain scans line up with the receptor?

Indirectly, yes. PET imaging in earlier studies produced an average map of where 5-HT2A receptors are densest in the human brain. In a 2023 EEG-fMRI study of intravenous DMT, maps of connectivity change weighted by how intense people rated the experience correlated with that independent receptor map; the strongest changes were in high-level “transmodal” cortex (Timmermann et al., 2023). The authors read this overlap as implying that increased 5-HT2A signalling causes the changes. Matching two maps from different people is a correlation, though, and the study had no receptor blocker. Evidence: preliminary.

For the full set of brain-imaging findings and their caveats, including the fact that fMRI measures blood flow rather than neurons, see what happens in the brain on DMT. Evidence: established for that caveat.

What is the intracellular 5-HT2A hypothesis?

Most textbook diagrams put 5-HT2A on the outside surface of neurons. A 2023 study showed that many of these receptors sit inside cortical neurons, and that it is the intracellular ones that drive the growth-promoting effects of psychedelics in cells and mice. In rat cortical neurons, DMT, which crosses cell membranes easily, promoted neuron growth; a chemically modified version that cannot cross membranes did so only when the membrane was temporarily opened by an electrical pulse. Serotonin itself, which does not cross membranes easily, only had this effect in neurons able to pump it inside. The authors say their work raises the possibility that serotonin might not be the natural partner for these intracellular receptors in the cortex (Vargas et al., 2023). Evidence: preliminary, from cells and rodents.

Steven Barker of Louisiana State University, author of several DMT reviews, has proposed the next step: that DMT is that missing natural partner, the brain’s own ligand for intracellular 5-HT2A receptors, and that this might also help explain the subjective effects of psychedelics in general (Barker, 2025). It is one researcher’s hypothesis. No study in any species has shown the brain’s own DMT acting on these receptors inside living neurons, and DMT has never been measured in a living human brain. Whether the brain makes meaningful amounts is covered in does the brain make DMT?. Evidence: unresolved.

What is still unknown?

• Whether blocking 5-HT2A before injected or inhaled DMT prevents its effects in people; the study has not been published (unresolved).
• How much 5-HT1A, sigma-1 and trace amine receptors add to DMT’s effects in humans (unresolved).
• Whether intracellular 5-HT2A receptors are where psychedelics, including DMT, act in the living human brain (unresolved).
• Whether DMT made in the body is a natural partner for intracellular 5-HT2A, as one researcher proposes (unresolved).

The fair summary: 5-HT2A is very probably DMT’s main switch, on strong evidence from mice, cells and ayahuasca, but the one human experiment that would settle it for pure DMT has not been published. Evidence: preliminary for pure DMT in people. For how this compares with psilocybin and LSD, see psilocybin, LSD and DMT: how they differ.

Shroomverse sells mushroom products. This article is general information about DMT and the serotonin 5-HT2A receptor. It is not medical, legal or purchasing advice, and it does not recommend any product.